Evidence of Sustained Vertebral and Nonvertebral Antifracture Efficacy with Ibandronate Therapy: A Systematic Review

Therapeutic Advances in Musculoskeletal Disease

Volumn 3, Issue 2, 2011, Pages 67-79

  Adami, Silvano ^a   Idolazzi, Luca ^a   Rossini, Maurizio ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

antifracture efficacy; bisphosphonates; bone mineral density; bone turnover markers; fracture; ibandronate; postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID;

BONE DENSITY; DATA BASE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; FRACTURE; HIGH RISK PATIENT; HUMAN; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VERTEBRA FRACTURE;

EID: 80053196392     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X10395651     Document Type: Article

References (60)

1. Adami S. Bianchi G. Brandi M.L. Giannini S. Ortolani S. DiMunno O. et al (2008) BONTURNO study group. Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int 82: 341–347.
2. Adami S. Felsenberg D. Christiansen C. Robinson J. Lorenc R.S. Mahoney P. et al (2004) Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34: 881–889.
3. Adami S. Miller P.D. Patel K. Schimmer R.C. Grant R. Recker R.R. (2007) Ibandronate-induced bone mineral density gains are related to vertebral antifracture efficacy. Calcif Tissue Int 80(Suppl. 1): s46 (Abstract P034-T).
4. Barrett J. Worth E. Bauss F. (2004) Ibandronate: A clinical pharmacological and pharma-cokinetic update. J Clin Pharmacol 44: 951–965.
5. Bauer D.C. Black D.M. Garnero P. Hochberg M. Ott S. Orloff J. et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. J Bone Miner Res 19: 1250–1258.
6. Bianchi G. Felsenberg D. Czerwinski E. (2009) Efficacy of IV ibandronate is maintained over 5 years: The DIVA LTE study. Ann Rheum Dis 68(Suppl. 3): 494.
7. Black D.M. Cummings S.R. Karpf D.B. Cauley J.A. Thompson D.E. Nevitt M.C. et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 1535–1541.
8. Black D.M. Delmas P.D. Eastell R. Reid I.R. Boonen S. Cauley J.A. et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809–1822.
9. Bliuc D. Nguyen N.D. Milch V.E. Nguyen T.V. Eisman J.A. Center J.R. (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301: 513–521.
10. Briggs A.M. Greig A.M. Wark J.D. (2007) The vertebral fracture cascade in osteoporosis: A review of aetiopathogenesis. Osteoporos Int 18: 575–584.
11. Brody B.A. Dickey N. Ellenberg S.S. Heaney R.P. Levine R.J. O'Brien R.L. et al (2003) Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis? J Bone Miner Res 18: 1105–1109.
12. Brown J.P. Kendler D.L. McClung M.R. Emkey R.D. Adachi J.D. Bolognese M.A. et al (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71: 103–111.
13. Browner W.S. Pressman A.R. Nevitt M.C. Cummings S.R. (1996) Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med 156: 1521–1525.
14. Chesnut C.H. Ettinger M.P. Miller P.D. Baylink D.J. Emkey R. Harris S.T. et al (2005) Ibandronate produces significant, similar antifracture efficacy in North American and European women: New clinical findings from BONE. Curr Med Res Opin 21: 391–401.
15. Chesnut C.H. Skag A. Christiansen C. Recker R. Stakkestad J.A. Hoiseth A. et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19: 1241–1249.
16. Chrischilles E.A. Butler C.D. Davis C.S. Wallis R.B. (1991) A model of lifetime osteoporosis impact. Arch Intern Med 151: 2026–2032.
17. Cranney A. Wells G.A. Yetisir E. Adami S. Cooper C. Delmas P.D. et al (2009) Ibandronate for the prevention of nonvertebral fractures: A pooled analysis of individual patient data. Osteoporos Int 20: 291–297.
18. Cummings S.R. Black D.M. Thompson D.E. Applegate W.B. Barrett-Connor E. Musliner T.A. et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280: 2077–2082.
19. Cummings S.R. Karpf D.B. Harris F. Genant H.K. Ensrud K. LaCroix A.Z. et al (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs. Am J Med 112: 281–289.
20. Cummings S.R. Melton J.L. (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359: 1761–1767.
21. Delmas P.D. Adami S. Strugala C. Stakkestad J.A. Reginster J.Y. Felsenberg D. et al (2006) Intravenous ibandronate injections in postmenopausal osteoporosis: 1-year findings from the DIVA study. Arthritis Rheum 54: 1838–1846.
22. Delmas P.D. Benhamou C.L. Man Z. Stakkestad J.A. Reginster J.Y. Felsenberg D. et al (2008) Monthly dosing of 75 mg risendronate on 2 consecutive days a month: Efficacy and safety results. Osteoporosis Int 19: 1039–1045.
23. Delmas P.D. Recker R.R. Chesnut C.H. Skag A. Stakkestad J.A. Enkey R. et al (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study. Osteoporos Int 15: 792–798.
24. Eastell R. Barton I. Hannon R.A. Chines A. Garnero P. Delmas P.D. (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18: 1051–1056.
25. Eisman J.A. Civitelli R. Adami S. Czerwinski E. Recknor C. Prince R. et al (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 35: 488–497.
26. Epstein S. Jeglitsch M. McCloskey E. (2009) Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: Focus on ibandronate 150 mg and risedronate 150 mg. Curr Med Res Opin 25: 2951–2960.
27. European Medicines Agency (2005) Guideline on the Evaluation of New Medicinal Products in the Treatment of Osteoporosis. Available at: http://www.emea.eu.int/pdfs/human/ewp/055295en.pdf.
28. Felsenberg D. Czerwinski E. Stakkestad J. Christiansen C. Civitelli R. Drezner M.K. et al (2009) Efficacy of monthly oral ibandronate is maintained over 5 years: The MOBILE LTE study. Osteoporos Int 20(Suppl. 1): S15, (Abstract 0C32).
29. Felsenberg D. Miller P. Armbrecht G. Wilson K. Schimmer R.C. Papapoulos S.E. (2005) Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 37: 651–654.
30. Felsenberg D. Recker R.R. Kenwright A. Masanauskaite D. Miller P.D. (2010) Suppression of bone turnover markers with monthly oral ibandronate is sustained over 5 years: The MOBILE LTE study. Osteoporosis Int 21(Suppl. 1): S194, (Abstract P477).
31. Geusens P. (2009) Bisphosphonates for postmenopausal osteoporosis: Determining duration of treatment. Curr Osteoporos Rep 7: 12–17.
32. Giangregorio L.M. Leslie, W.D. for the Manitoba Bone Density Program (2010) Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res 25: 1400–1405.
33. Grimes D.A. Schultz K. (2002) Bias and casual associations in observational research. Lancet 359: 248–252.
34. Harris S.T. Blumentals W.A. Miller P.D. (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: Results of a meta-analysis of phase III studies. Curr Med Res Opin 24: 237–245.
35. Harris S.T. Reginster J.Y. Harley C. Blumentals W.A. Poston S.A. Barr C.E. et al (2009) Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The e Valuation of IBandronate Efficacy (VIBE) database fracture study. Bone 44: 758–765.
36. Harris S.T. Watts N.B. Genant H.K. McKeever C.D. Hangartner T. Keller M. et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. J Am Med Assoc 282: 1344–1352.
37. Hochberg M.C. Greenspan S. Wasnich R.D. Miller P. Thompson D.E. Ross P.D. (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinal Metab 87: 1586–1592.
38. Hochberg M.C. Ross P.D. Black D. Cummings S.R. Genant H.K. Nevitt M.C. et al (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arth Rheum 42: 1246–1254.
39. Ismail A.A. O'Neill T.W. Cooper C. Finn J.D. Bhalia A.K. Cannata J.B. et al (1998) Mortality associated with vertebral deformity in men and women: Results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 8: 291–297.
40. Johnell O. Kanis J.A. (2004) An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15: 897–902.
41. Johnell O. Kanis J.A. (2005) Epidemiology of osteoporotic fractures. Osteoporos Int 16(Suppl. 2): S3–S7.
42. Johnell O. Kanis J.A. (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17: 1726–1733.
43. Melton J.A. Johnell O. Lau E. Mautalen C.A. Seeman E. (2004) Osteoporosis and the global competition for health care resources. J Bone Miner Res 19: 1055–1058.
44. Melton L.J. III (2003) Adverse outcomes of osteoporotic fractures in the general population. J Bone Min Res 18: 1139–1141.
45. Miller P.D. McClung M.R. Macovei L. Stakkestad J.A. Luckey M. Bonvoisin B. et al (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20: 1315–1322.
46. Oleksik A. Lips P. Dawson A. Minshall M.E. Shen W. Cooper C. et al (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 5: 1384–1392.
47. Rabenda V. Manette C. Lemmens R. Mariani A.M. Stravay N. Reginster J.Y. et al (2007) Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clin Exp Res 19: 55–60.
48. Recker R. Stakkestad J.A. Chesnut C.H. Christiansen C. Skag A. Hoiseth A. et al (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34: 890–899.
49. Reginster J. Minne H.W. Sorensen O.H. Hooper M. Roux C. Brandi M.L. et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11: 83–91. “.
50. Reginster J.Y. Adami S. Lakatos P. Greenwald M. Stepan J.J. Silverman S.L. et al (2006) Efficacy and tolerability of once-monthly oral ibandronate in post-menopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65: 654–661.
51. Rizzoli R. Greenspan S.L. Bone G. Schnitzer T.J. Watts N.B. Adami S. et al (2002) Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17: 1988–1996.
52. Rossini M. Viapiana O. Gatti D. Adami S. (2009) Once-monthly oral ibandronate in postmenopausal osteoporosis: Translation and updated review. Clin Ther 31: 1497–1510.
53. Sambrook P. Cooper C. (2006) Osteoporosis. Lancet 367: 2010–2018.
54. Sebba A. (2009) Comparing non-vertebral fracture risk reduction with osteoporosis therapies: Looking beneath the surface. Osteoporos Int 20: 675–686.
55. Silverman S.L. (2010) Osteoporosis therapies: Evidence from health-care databases and observational population studies. Calcif Tissue Int 87: 375–384.
56. Silverman S.L. Watts N.B. Delmas P.D. Lang J.L. Lindsay R. (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study. Osteoporos Int 18: 25–34.
57. Stakkestad J.A. Lakatos P. Lorenc R. Sedarati F. Neate C. Reginster J.Y. (2008) Monthly oral ibandronate is effective and well tolerated after 3 years: The MOBILE long-term extension. Clin Rheumatol 27: 955–960.
58. Temple R.J. (2003) Study designs in osteoporosis. J Bone Miner Res 18: 1129–1132.
59. Tosteson A.N. Gabriel S.E. Grove M.R. Moncur M.M. Kneeland T.S. Melton L.J. III (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12: 1042–1049.
60. Wasnich R. Miller P. (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin End Metab 85: 231–232.